Grenzacherstrasse 124
Basel, Basel-Stadt (Basle
Phone: 41.61.688.11.11
http://www.roche.com
Roche Holding AG (OTC: RHHBY ) is reportedly contemplating the divestiture of Flatiron Health , a cancer data specialist Roche acquired in 2018 for $1.9 billion. The move underscores the complexities and potential pitfalls that large pharmaceutical companies encounter when investing in early-stage health technology firms. Also Read: Roche’s New Immunotherapy Fails To Show Benefit Over Merck’s Blockbuster Keytruda In Lung Cancer Patients . Flatiron Health was founded by two former executives from Alphabet Inc’s (NASDAQ: GOOG ) (NASDAQ: GOOGL ) Google. The company manages electronic patient records for numerous U.S. cancer clinics, boasting one of the most extensive repositories of cancer data. The start-up mines this data and sells it to … Full story available on Benzinga.com
No summary available.
… US pharmaceuticals firm Eli Lilly and Danish Novo Nordisk in the slimming drugs market … is threatened. Two firms, Viking Therapeutics and Roche , announced … estimates the market for such drugs will grow from €14 billion …
Roche had paid $1.9 billion for New-York based Flatiron Health in 2018 to speed its development of cancer medicines and support its efforts to price them based on how well they work.
https://www.investing.com/news/stock-market-news/roche-considering-divesting-19-billion-cancer-data-startup-ft-reports-3558321
Swiss pharmaceutical giant Roche Holding AG has inked … Tuesday through Roche ’s Genentech research arm. Roche has licensed … diseases. This agreement grants Roche exclusive rights to molecules … Alzheimer’s disease. Additionally, Roche has secured rights to …
No summary available.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has entered into a license agreement with Genentech, a member of the Roche Group, to develop intravenously administered genomic medicines to treat certain neurodegenerative diseases. Sangamo has granted Genentech an exclusive license to Sangamo’s proprietary zinc finger repressors that are directed to the Jetzt den vollständigen Artikel lesen
https://www.investing.com/news/company-news/roche-shares-target-increased-by-berenberg-on-carmot-acquisition-impact-93CH-3556097
… Eli Lilly and Novo Nordisk on the stock market. The two pharmaceutical … producing and marketing anti-obesity drugs . However, this is a … risen by 235%. Similarly, Roche — which had previously announced … facing Novo Nordisk and Eli Lilly was meeting the huge …